July 21, 2008 - Rexahn Pharmaceuticals, Inc., a leader in innovative therapeutics for life-threatening and life-debilitating diseases, today announced that the U.S. Patent & Trademark Office has issued to the Company U.S. Patent 7,388,014, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."
Patent 7,388,014 covers Rexahn's anticancer candidate, RX-0183 and related compounds, and are targeted, small molecule quinazoline analogues that inhibit key molecules such as c-Fos and Akt proteins. Akt and c-Fos proteins are cancer cell signaling targets involved in transduction, growth and proliferation. Preclinical studies showed that RX-0183 inhibited in vitro proliferation of cancer cells derived from many human solid tumors. It also inhibited tumor growth in xenograft human tumor models. Based on the preclinical data, RX-0183 demonstrates potent anticancer activity for treating multiple cancers.
The details can be read here.
No comments:
Post a Comment